Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 592

Sort by

Sort Order Select

Journal Articles

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Shufen Cao, Gouri Dharmavaram, Kirsten M Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Pingfu Fu, Paolo F Caimi, MD

Blood (2019) 134 (Supplement_1): 4770.

https://doi.org/10.1182/blood-2019-131527

Published: 2019

Journal Articles

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Mitsuhiro Yuasa, MD, Daisuke Kaji, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD

Blood (2019) 134 (Supplement_1): 1529.

https://doi.org/10.1182/blood-2019-130837

Published: 2019

Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 1580.

https://doi.org/10.1182/blood-2019-126115

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Guy Bitansky, Elena Vasilev, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD, Meirav Kedmi, MD

Blood (2019) 134 (Supplement_1): 1534.

https://doi.org/10.1182/blood-2019-125218

Published: 2019

Journal Articles

Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study

Blood (2019) 134 (Supplement_1): 1539.

https://doi.org/10.1182/blood-2019-125835

Published: 2019

Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 1533.

https://doi.org/10.1182/blood-2019-129311

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Jonas Paludo, MD, Surendra Dasari, PhD, Kerstin Wenzl, PhD, Shahrzad Jalali, PhD, Jordan Krull, Michelle Manske, MS, BS, Esteban Braggio, PhD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, MD, Craig B. Reeder, MD, Allison C. Rosenthal, DO, Robert A. Kyle, MD, Morie A Gertz, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2774.

https://doi.org/10.1182/blood-2019-128912

Published: 2019

Journal Articles

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

Ida Monrad, MSc, Charlotte Madsen, Kristina Lauridsen, Bent Honoré, Trine Lindhardt Plesner, Stephen Hamilton-Dutoit, MD, Francesco d'Amore, MD, Maja Ludvigsen, MSc, PhD

Blood (2019) 134 (Supplement_1): 2805.

https://doi.org/10.1182/blood-2019-122651

Published: 2019

Journal Articles

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Clare Gould, Colm Keane, MD, Valentine Murigneux, M.Sc., Harald Oey, Jonathan Ellis, PhD, Simone Birch, MBBS, Jay Gunawardana, PhD, Dipti Talaulikar, Mark S. Hertzberg, MD PhD, Kimberley Jones, Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): 2778.

https://doi.org/10.1182/blood-2019-126537

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

David Andorsky, MD, Rebecca J Chan, MD PhD, Jamyia Clark, MPH, Bianca Ruzicka, PhD, Nicholas James Robert, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 2810.

https://doi.org/10.1182/blood-2019-124013

Published: 2019

Journal Articles

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Maryam Sarraf Yazdy, MD, Umair Jarral, MD, Chao Yin, MD, Frank Kuhr, PhD, Allison P. Jacob, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2813.

https://doi.org/10.1182/blood-2019-127262

Published: 2019

Journal Articles

Optimal Cycles of Bendamustine-Plus Rituximab Therapy for Indolent B Cell Lymphoma

Kazuhiro Toyama, MD PhD, Toshiaki Takezaki, MD, Akira Honda, MD PhD, Yasunori Kogure, MD PhD, Akira Chiba, MD, Fumihiko Nakamura, MD PhD, Kumi Nakazaki, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5242.

https://doi.org/10.1182/blood-2019-124597

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma

Sanjal Desai, MD, Stephen Fernandez, Anusha Vakiti, MD, Facundo Stingo, MD, Tripti Adhikari, MD, Emily Paku, Aarthi Shenoy, MD, Vera Malkovska, MD, Dawn Fishbein, MD

Blood (2019) 134 (Supplement_1): 1614.

https://doi.org/10.1182/blood-2019-127520

Published: 2019

Journal Articles

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Stefania Bettelli, Raffaella Marcheselli, Samantha Pozzi, MD, Luigi Marcheselli, Robel Papotti, Elisa Forti, M. Christina Christina Cox, MD PhD, Arianna Di Napoli, Tamar Tadmor, MD, Antonino Maiorana, Valentina Donati, MD, Sara Galimberti, MD PhD, Stefano Sacchi, MD

Blood (2019) 134 (Supplement_1): 1617.

https://doi.org/10.1182/blood-2019-125689

Published: 2019

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Optimal Cycles of Bendamustine-Plus Rituximab Therapy for Indolent B Cell Lymphoma

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only